Since 1995 I have had the interesting experience of working as a neurologist in a large state prison whose primary mission is to provide medical care to inmates. A large proportion of my practice ...

Please provide your email address to receive an email when new articles are posted on . Wainua has received regulatory approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis.

The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in ...

This page lists all known medications that could potentially lead to 'Polyneuropathy' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among adults with type 2 diabetes, those reporting ...

Hereditary transthyretin amyloidosis (hATTR) is a rare inherited disorder that gets worse over time. It often affects the nerves, heart, liver, and kidneys, but it can also affect other organs.

– EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo – CARLSBAD, ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...

Polyneuropathy is one of the most common complications in people with diabetes. First symptoms are often pins-and-needles sensations in the feet. Although polyneuropathy is present in about 30 percent ...

Amvuttra is a subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein. The Food and Drug Administration (FDA) has approved Amvuttra ...

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years. Netherlands-based argenx has announced that the Committee for ...